Alkem Laboratories Under Pressure Post Form 483 Notice

remains in focus after the US Food and Drug Administration inspected its Amaliya, Daman facility from April 20 to May 1. Post inspection, the company received a Form 483 with seven observations, indicating areas requiring corrective action. Reacting to the development, the stock saw mild pressure in early trade, falling as much as 0.98%. However, it recovered partially and was trading down 0.42% at 10:20 AM, suggesting limited downside impact so far. Form 483 observations are procedural in nature, and markets typically monitor the company’s response and resolution timeline closely. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.